This federal contract award (SPE2DP16D0008|0008) was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the delivery of oseltamivir phosphate (the active ingredient in Tamiflu). The $143,455.80 firm fixed-price delivery order contract has a period of performance through September 20, 2017. This award is associated with a larger indefinite delivery contract between Genentech and the DLA, valued at $27.9 million, to provide medical supplies and critical pharmaceuticals to the Department of Defense's global health logistics network. The contract does not have a set-aside designation.